Special Issue "Emerging Issues in COVID-19 and Neutralizing Antibodies"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 75739
The ongoing COVID-19 pandemic has caused millions of deaths worldwide, and counting. Small-chemical antivirals and immunosuppressive treatments are not always efficacious, but passive and active immunotherapies based on neutralizing antibodies show potential.
Antibody immune response is important for the clearance of the virus and critical for the generation of memory response to prevent reinfection. SARS-CoV-2 generates a virus-specific IgM, IgG and neutralizing antibody response in the days following infection. However, these antibody responses wane over time and in some cases contribute to only partial protection. There is a need for further research in this field to understand the measures of and the magnitude of antibody responses and their relationship with longer-term protection conferred by vaccines, vaccine combinations, vaccine-driven pathology, and immune differences among vaccines and patients. This necessitates a critical evaluation of vaccine efficiency in different patient groups and for vaccine research to be expedited.
In this Special Issue, we invite articles investigating antibody responses to coronavirus, including but not limited to the role of neutralizing antibodies in SARS-CoV-2 infection, mechanisms that lead to viral escape, immune parameters correlated with cytokine release syndrome, and T-cell and B-cell dynamics in coronavirus infection.
Prof. Dr. Tar Choon Aw
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune escape
- neutralizing antibodies
- sterilizing immunity